Introduction
Next Steps and Innovations for Accelerated Growth
In surgery, every decision counts. Medistim’s MiraQ transit time flow measurement (TTFM) and high-frequency ultrasound (HFUS) imaging devices play a critical role in supporting surgeons and their teams in the operating room – where the decisions can mean the difference between life and death for patients.
In the midst of complex Cardiac, Vascular, and Transplant surgeries, Medistim is there to streamline workflows, simplify data interpretation, and enhance the surgical team’s confidence, particularly when reassessing a graft is crucial.
We actively listen to their feedback and experiences, and it is our pledge to continually improving our solutions to make their work—and their lives—easier. This commitment drives our dedication to innovation in both product development and clinical research.
At this Capital Markets Day, you’ll be introduced to INTUI, our software platform that will be launched on December 13th 2024 at the ICC congress. INTUI is designed to enhance decision-making in coronary artery bypass graft (CABG) surgery. You’ll also hear about PATENT, a new clinical study in Peripheral Bypass surgery that has the potential to become a landmark in the use of TTFM and HFUS imaging for treating critical limb-threatening ischemia (CLTI).
You’ll have the opportunity to engage with world-renowned experts as they share their experiences and insights on the future of these vital surgical fields.
And finally, you will learn how these initiatives will help drive adoption of Medistim’s devices in Cardiac, Vascular and Transplant surgery.
